Mario Mandalà
University of Perugia(IT)Azienda Ospedaliera di Perugia(IT)Ospedale Santa Maria(IT)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma(2014)2,015 cited
- → Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer(2018)1,796 cited
- → Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma(2017)1,459 cited